ITM to Speak at Oppenheimer’s Annual Healthcare Conference

Garching / Munich, February 7, 2025 –  ITM Isotope Technologies Munich SE, a leading radiopharmaceutical biotech company, will participate in Oppenheimer’s 35^th Annual Healthcare Life Sciences Conference. CEO Dr. Andrew Cavey will present a virtual corporate overview of ITM’s radiopharmaceutical pipeline, opportunities, and upcoming milestones on Tuesday, February 11, 2025, at 8:40 AM ET.

For further information, please contact:

Investor Relations
Ben Orzelek
Phone: +49 89 329 8986 1009
Email: 

Media Contact
Corporate Communications
Kathleen Noonan/Julia Westermeir
Phone: +49 89 329 8986 1500
Email:
 
About ITM Isotope Technologies Munich SE
ITM is a leading radiopharmaceutical biotech company focused on developing next-generation radiopharmaceutical therapeutics and diagnostics for difficult-to-treat cancers. We are committed to serving cancer patients, clinicians, and partners through excellence in development, manufacturing, and global distribution. Driven by improved patient outcomes, ITM is advancing a comprehensive precision oncology pipeline, including multiple Phase 3 trials, combining high-quality radioisotopes with various targeting molecules. Leveraging two decades of expertise, a central industry role, and a global network, ITM aims to provide patients with more effective targeted therapies to enhance clinical results and quality of life. 

Attachment